Our people

our peopleHaving already headed up successful drug development companies, Chief Executive Officer Ian Garland and Chief Financial Officer David Mackney are the perfect team to help Vernalis realise its potential.  They form part of a talented, highly qualified and knowledgeable senior management team that lead our commercial pipeline, manage our research programmes and oversee our NCE partner collaborations.

Our US Executive team is headed by Sandford Somner, who joined in May 2015 as President and Chief Operating Officer Vernalis Therapeutics, Inc., and by three Senior Vice Presidents covering Commercial, Pharmaceutical Quality Operations and Medical Affairs.

By leveraging our skills in research, our team secured multiple collaborations, including a new collaboration with Taisho during 2015, and we aim to continue to build on this success. 

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch